Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05646758
Other study ID # TQB2934-I-01
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date March 17, 2023
Est. completion date October 2025

Study information

Verified date February 2024
Source Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Contact Peng Liu, Doctor
Phone 021-60267405
Email Liu.peng@zs-hospital.sh.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

TQB2934 is an anti-CD3(Early T Cell Marker)×BCMA (B cell maturation antigen) double-specific antibody,and the isoform is IgG1 (Native Immunoglobulin G1), which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA(B cell maturation antigen) to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.TQB2934 for injection is planned for the treatment of patients with multiple myeloma.


Recruitment information / eligibility

Status Recruiting
Enrollment 140
Est. completion date October 2025
Est. primary completion date October 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - The subjects volunteered to join the study and signed informed consent form (ICF)with good compliance; - Age: = 18 years old (when signing ICF); ECOG PS score: 0-1; The expected survival period is more than 3 months; - Multiple myeloma with diagnostic records and meeting the IMWG diagnostic criteria; - In the presence of measurable lesions, at least one of the following criteria must be met: 1. Serum monoclonal immunoglobulin (M protein)=1.0g/dL,or urine M protein=200mg/24h; 2. Light chain type: serum immunoglobulin free light chain (FLC) = 10 mg/dL, and the ratio of free light chain serum immunoglobulin ? and ? is abnormal; - Relapsed or refractory multiple myeloma who have received at least 1 line of therapy in the past, and are refractory to at least 1 proteasome inhibitor (PI), 1 immunomodulator (IMiD) and 1 CD38 monoclonal antibody; - Disease progression during or within 12 months after the last treatment (meeting the PD criteria of IMWG), including refractory or no remission of the last treatment (=1 cycle) or disease progression within 6 months; - Major organ function is good; - Female subjects of childbearing age should agree to use contraceptive measures (such as intrauterine devices, contraceptives or condoms) during the study period and within 6 months after the end of the study; serum pregnancy/urine pregnancy test within 7 days before study enrollment; Exclusion Criteria: - Comorbidities and medical history: 1. Other malignant tumors have occurred or are currently suffering from other malignant tumors within 3 years before the first medication. 2. Unresolved toxic reactions higher than CTC AE grade 1 or higher due to any previous treatment, excluding alopecia, fatigue and peripheral neuropathy; 3. Major surgical intervention, open biopsy, or significant traumatic injury within 28 days prior to first dose; 4. long-term unhealed wounds or fractures; 5. Hyperactive/venous thrombosis events occurred within 6 months before the first medication, such as cerebrovascular accidents (including transient ischemic attacks, cerebral hemorrhage, cerebral infarction), deep vein thrombosis and pulmonary embolism, etc.; 6. Those who have a history of psychotropic drug abuse and cannot quit or have mental disorders; 7. Subjects with any severe and/or uncontrolled disease,include: 1. Unsatisfactory blood pressure control (systolic blood pressure = 160 mmHg or diastolic blood pressure = 100 mmHg, at least 2 measurements at intervals of more than 24 hours); 2. Myocardial infarction, unstable angina, CTC AE = grade 2 stable angina, = grade 2 heart failure (New York Heart Association (NYHA) classification), = grade 2 arrhythmia occurred within 6 months before the first medication; 3. Cardiac ultrasound evaluation: left ventricular ejection fraction (LVEF) <50%; 4. Active or uncontrolled severe bacterial, viral or systemic fungal infection within 28 days before the first dose (=CTC AE grade 2 infection); 5. Hepatitis (meeting one of the following criteria: hepatitis B: HBV DNA detection value exceeds the upper limit of normal value; hepatitis C: HCV RNA detection value exceeds the upper limit of normal value) or decompensated cirrhosis (Child-Pugh grade B, C grade; 6. Chronic obstructive pulmonary disease (COPD) and forced expiratory volume in 1 second (FEV1) <60% of predicted value. 7. Has developed or currently suffered from asthma within 2 years before the first medication; 8. A history of immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency diseases, or a history of solid organ transplantation (except corneal transplantation), and active or autoimmune patients who need to receive systemic immunosuppressant therapy; 9. Poorly controlled diabetes (fasting blood glucose (FBG) >10mmol/L); 10. Suffering from epilepsy and needing treatment; - Tumor-related symptoms and treatment: 1. Diagnosed with amyloidosis, plasma cell leukemia (PCL, peripheral plasma cell ratio = 20%, or absolute plasma cell count = 2×109/L), Waldenstrom macroglobulinemia (WM) or POEMS syndrome; 2. Known multiple myeloma meningeal or central nervous system invasion or highly suspected meningeal or central nervous system invasion but cannot be identified; 3. Previously received BCMA-targeted therapy; 4. Previously received allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor T (CAR-T), CAR-NK cell therapy; or received autologous hematopoietic stem cell transplantation (ASCT) within 12 weeks before the first drug; 5. Received targeted therapy, cytotoxic drugs or any antibody therapy within 3 weeks before the first medication; received proteasome inhibitor therapy or radiotherapy within 2 weeks before the first medication; received immunomodulator therapy within 1 week before the first medication.(Prophylaxis to prevent infusion-related reactions prior to study drug administration)(Calculate the washout period from the end of the last treatment); - research treatment related: 1. History of live attenuated vaccine vaccination within 28 days before the first dose or planned live attenuated live vaccine vaccination during the study; 2. Unexplained severe allergy history, known allergy to monoclonal antibody drugs or exogenous human immunoglobulin, or known allergy to TQB2934 for injection or excipients in pharmaceutical preparations; - Those who have participated in other anti-tumor drug clinical trials within 4 weeks before the first drug use or have not exceeded 5 drug half-lives; - According to the investigator's judgment, there are concomitant diseases that seriously endanger the safety of the subjects or affect the completion of the study, or subjects who are considered unsuitable for enrollment for other reasons;

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
TQB2934 injection
TQB2934 is an anti-CD3×BCMA double-specific antibody,which at one end binds to the CD3 receptor on the surface of T cells ,and the other end binds to BCMA to recruit T cells around BCMA-positive cells, which can activate T cells .Active T cells release granzyme and perforin to kill BCMA-positive target cells.

Locations

Country Name City State
China Peking Union Medical College Hospital Beijing Beijing
China Sun Yat-Sen University Cancer Canter Guangzhou Guangdong
China Shandong First Medical University Affiliated Tumor Hospital Jinan Shandong
China Zhongshan Hospital of Fudan University Shanghai Shanghai
China The Second Affiliated Hospital of Soochow University Suzhou Jiangsu
China The First Affiliated Hospital of Wenzhou Medical University Wenzhou Zhejiang
China The Henan Cancer Hospital Zhengzhou Henan

Sponsors (1)

Lead Sponsor Collaborator
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Dose-limiting toxicity (DLT) DLT refers to any of the toxicity events in the first administration of TQB2934 for injection to the end of the first treatment cycle. Up to 18 months
Primary Maximum Tolerated Dose (MTD) After the trial, ordinal regression was used to determine the maximum tolerated dose (MTD) Up to 18 months
Primary Incidence and severity of serious adverse events (AEs) Incidence and severity of serios adverse events (AEs) will be reported for safety evaluation. Up to 18 months
Primary Incidence and severity of adverse events (AEs) Incidence and severity of adverse events (AEs) will be reported for safety evaluation. Up to 18 months
Primary Incidence and severity abnormal laboratory test value Incidence and severity abnormal laboratory test value will be reported for safety evaluation. Up to 18 months
Secondary Elimination half-life (t1/2) t1/2 is time it takes for the blood concentration of TQB2934 to drop by half. 120 hours after administration
Secondary Area under the plasma concentration-time curve (AUC0-last) To characterize the pharmacokinetics of TQB2934 by assessment of area under the plasma concentration time curve. 120 hours after administration
Secondary Apparent clearance (CL) Apparent clearance (CL) after administration 120 hours after administration
Secondary Terminal phase apparent volume of distribution (Vz) Terminal phase apparent volume of distribution (Vz) 120 hours after administration
Secondary Plasma trough concentration (Cmin) Cmin is the minimum plasma concentration of TQB2934. 120 hours after administration
Secondary Overall response rate (ORR) Proportion of subjects with best response as PR(Partial relief), VGPR(Very good partial relief), CR(Complete Response), sCR(Strict Complete Response) Up to 18 months
Secondary Clinical benefit rate (CBR) Proportion of subjects with best response as MR(Minor relief), PR(Partial relief), VGPR(Very good partial relief), CR(Complete Response), sCR(Strict Complete Response) Up to 18 months
Secondary Very good partial response rate (VGPR) Proportion of subjects whose best response is VGPR, CR, sCR; Up to 18 months
Secondary Complete Response (CR) / Strict Complete Response (sCR) Rate Proportion of subjects whose best response is CR and sCR; Up to 18 months
Secondary Negative rate of minimal residual disease (MRD) The proportion of subjects with negative MRD (<10-5, multicolor flow cytometry or next-generation sequencing) at any time point from the first administration of the trial drug to disease progression or before receiving new anti-tumor therapy; Up to 18 months
Secondary Duration of remission (DOR) For all subjects whose best response was PR, VGPR, CR, sCR, the time from the date of first achieving PR, VGPR, CR, sCR to the date of first definite disease progression or (any cause) death(whichever occurs first). Up to 18 months
Secondary Time to first remission (TTR) Among all the subjects whose best response is PR, VGPR, CR, sCR, the time from the first administration of the test drug to the date of the first PR and above remission. Up to 18 months
Secondary Progression-free survival (PFS) The time between the first dose of the trial drug and the date of first definite disease progression or death (from any cause), whichever occurs first. Up to 18 months
Secondary Overall survival (OS) Time from first dose of study drug to date of death from any cause. Up to 18 months
Secondary Disease status was determined using the International Myeloma Working Group (IMWG) 2016 criteria Disease status was determined using the International Myeloma Working Group (IMWG) 2016 criteria Up to 18 months
Secondary Antidrug antibody (ADA) incidence Positive incidence of anti-drug antibodies Up to 18 months
Secondary Peripheral blood soluble BCMA (sBCMA) level The level of soluble BCMA (sBCMA) in peripheral blood is the pharmacodynamic index of TQB2934. Up to 18 months
Secondary Receptor occupancy rate (RO) The receptor occupation (RO) of TQB2934 on immune cells in human body Up to 18 months
Secondary Cytokine Interleukin 2 (IL-2) levels The level of cytokine interleukin 2 (IL-2) is the pharmacodynamic index of TQB2934. Up to 18 months
Secondary Cytokine Interleukin 6 (IL-6) levels The level of cytokine interleukin 6 (IL-6) is the pharmacodynamic index of TQB2934. Up to 18 months
Secondary Cytokine Interleukin 10 (IL-10) levels The level of cytokine interleukin 10 (IL-10) is the pharmacodynamic index of TQB2934. Up to 18 months
Secondary Cytokine Interferon ? (IFN-?) levels The level of cytokine Interferon ? (IFN-?) is the pharmacodynamic index of TQB2934. Up to 18 months
Secondary Cytokine Interferon a (IFN-a) levels The level of cytokine Interferon a (IFN-a) is the pharmacodynamic index of TQB2934. Up to 18 months
See also
  Status Clinical Trial Phase
Recruiting NCT05027594 - Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02412878 - Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma Phase 3
Completed NCT01947140 - Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies Phase 1/Phase 2
Recruiting NCT05971056 - Providing Cancer Care Closer to Home for Patients With Multiple Myeloma N/A
Recruiting NCT05243797 - Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation Phase 3
Active, not recruiting NCT04555551 - MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma Phase 1
Recruiting NCT05618041 - The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies N/A
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Completed NCT02916979 - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG Phase 1
Recruiting NCT03570983 - A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion Phase 2
Completed NCT03665155 - First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody Phase 1/Phase 2
Terminated NCT03399448 - NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells) Phase 1
Completed NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Active, not recruiting NCT03989414 - A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM) Phase 1/Phase 2
Active, not recruiting NCT03792763 - Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients Phase 2
Withdrawn NCT03608501 - A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation Phase 2
Recruiting NCT04537442 - Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma Phase 1
Completed NCT02546167 - CART-BCMA Cells for Multiple Myeloma Phase 1